Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing

Sinchita Roy-Chowdhuri, Debora De Melo Gagliato, Mark J. Routbort, Keyur P. Patel, Rajesh R. Singh, Russell Broaddus, Alexander J. Lazar, Aysegul Sahin, Ricardo H. Alvarez, Stacy Moulder, Jennifer J. Wheler, Filip Janku, Ana M. Gonzalez-Angulo, Mariana Chavez-MacGregor, Vicente Valero, Naoto T. Ueno, Gordon Mills, John Mendelsohn, Hui Yao, Kenneth AldapeRajyalakshmi Luthra, Funda Meric-Bernstam

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objectives: The advent of next-generation sequencing (NGS) platforms in the realm of clinical molecular diagnostics provides multigene mutational profiling through massively parallel sequencing. Methods: We analyzed 415 breast carcinoma samples from 354 patients using NGS in known hotspots of 46 commonly known cancer-causing genes. Results: A total of 281 somatic nonsynonymous mutations were detected in 62.1% of patients. TP53 was most frequently mutated (38.8%), followed by PIK3CA (31.7%), AKT1 (6%), and ATM (3.9%), with other mutations detected at a lower frequency. When stratified into clinically relevant therapeutic groups (estrogen receptor [ER]/progesterone receptor [PR]+ human epidermal growth factor receptor 2 [HER2]-, ER/PR+HER2+, ER/PR-HER2+, ER/PR/HER2-), each group showed distinct mutational profiles. The ER/PR+HER2- tumors (n = 132) showed the highest frequency of PIK3CA mutations (38%), while the triple-negative tumors (n = 64) had a significantly higher number of TP53 mutations (62%). Of the 61 patients tested for both primary and metastatic tumors, concordant results were seen in 47 (77%) patients, while 13 patients showed additional mutations in the metastasis. Conclusions: Our results indicate that breast cancers may harbor potentially actionable mutations for targeted therapeutics. Therefore, NGS-based mutational profiling can provide useful information that can guide targeted cancer therapy.

Original languageEnglish (US)
Pages (from-to)713-721
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume144
Issue number5
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
Mutation
Neoplasms
High-Throughput Nucleotide Sequencing
Molecular Pathology
Neoplasm Genes
Mutation Rate
Therapeutics
human ERBB2 protein
Neoplasm Metastasis

Keywords

  • Breast carcinoma
  • ER positive
  • Mutational profiling
  • Next-generation sequencing
  • Triple negative

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Roy-Chowdhuri, S., De Melo Gagliato, D., Routbort, M. J., Patel, K. P., Singh, R. R., Broaddus, R., ... Meric-Bernstam, F. (2015). Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. American Journal of Clinical Pathology, 144(5), 713-721. https://doi.org/10.1309/AJCPWDEQYCYC92JQ

Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. / Roy-Chowdhuri, Sinchita; De Melo Gagliato, Debora; Routbort, Mark J.; Patel, Keyur P.; Singh, Rajesh R.; Broaddus, Russell; Lazar, Alexander J.; Sahin, Aysegul; Alvarez, Ricardo H.; Moulder, Stacy; Wheler, Jennifer J.; Janku, Filip; Gonzalez-Angulo, Ana M.; Chavez-MacGregor, Mariana; Valero, Vicente; Ueno, Naoto T.; Mills, Gordon; Mendelsohn, John; Yao, Hui; Aldape, Kenneth; Luthra, Rajyalakshmi; Meric-Bernstam, Funda.

In: American Journal of Clinical Pathology, Vol. 144, No. 5, 01.01.2015, p. 713-721.

Research output: Contribution to journalArticle

Roy-Chowdhuri, S, De Melo Gagliato, D, Routbort, MJ, Patel, KP, Singh, RR, Broaddus, R, Lazar, AJ, Sahin, A, Alvarez, RH, Moulder, S, Wheler, JJ, Janku, F, Gonzalez-Angulo, AM, Chavez-MacGregor, M, Valero, V, Ueno, NT, Mills, G, Mendelsohn, J, Yao, H, Aldape, K, Luthra, R & Meric-Bernstam, F 2015, 'Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing', American Journal of Clinical Pathology, vol. 144, no. 5, pp. 713-721. https://doi.org/10.1309/AJCPWDEQYCYC92JQ
Roy-Chowdhuri S, De Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R et al. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. American Journal of Clinical Pathology. 2015 Jan 1;144(5):713-721. https://doi.org/10.1309/AJCPWDEQYCYC92JQ
Roy-Chowdhuri, Sinchita ; De Melo Gagliato, Debora ; Routbort, Mark J. ; Patel, Keyur P. ; Singh, Rajesh R. ; Broaddus, Russell ; Lazar, Alexander J. ; Sahin, Aysegul ; Alvarez, Ricardo H. ; Moulder, Stacy ; Wheler, Jennifer J. ; Janku, Filip ; Gonzalez-Angulo, Ana M. ; Chavez-MacGregor, Mariana ; Valero, Vicente ; Ueno, Naoto T. ; Mills, Gordon ; Mendelsohn, John ; Yao, Hui ; Aldape, Kenneth ; Luthra, Rajyalakshmi ; Meric-Bernstam, Funda. / Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. In: American Journal of Clinical Pathology. 2015 ; Vol. 144, No. 5. pp. 713-721.
@article{6846aba2db1b41faaec8a4339440d983,
title = "Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing",
abstract = "Objectives: The advent of next-generation sequencing (NGS) platforms in the realm of clinical molecular diagnostics provides multigene mutational profiling through massively parallel sequencing. Methods: We analyzed 415 breast carcinoma samples from 354 patients using NGS in known hotspots of 46 commonly known cancer-causing genes. Results: A total of 281 somatic nonsynonymous mutations were detected in 62.1{\%} of patients. TP53 was most frequently mutated (38.8{\%}), followed by PIK3CA (31.7{\%}), AKT1 (6{\%}), and ATM (3.9{\%}), with other mutations detected at a lower frequency. When stratified into clinically relevant therapeutic groups (estrogen receptor [ER]/progesterone receptor [PR]+ human epidermal growth factor receptor 2 [HER2]-, ER/PR+HER2+, ER/PR-HER2+, ER/PR/HER2-), each group showed distinct mutational profiles. The ER/PR+HER2- tumors (n = 132) showed the highest frequency of PIK3CA mutations (38{\%}), while the triple-negative tumors (n = 64) had a significantly higher number of TP53 mutations (62{\%}). Of the 61 patients tested for both primary and metastatic tumors, concordant results were seen in 47 (77{\%}) patients, while 13 patients showed additional mutations in the metastasis. Conclusions: Our results indicate that breast cancers may harbor potentially actionable mutations for targeted therapeutics. Therefore, NGS-based mutational profiling can provide useful information that can guide targeted cancer therapy.",
keywords = "Breast carcinoma, ER positive, Mutational profiling, Next-generation sequencing, Triple negative",
author = "Sinchita Roy-Chowdhuri and {De Melo Gagliato}, Debora and Routbort, {Mark J.} and Patel, {Keyur P.} and Singh, {Rajesh R.} and Russell Broaddus and Lazar, {Alexander J.} and Aysegul Sahin and Alvarez, {Ricardo H.} and Stacy Moulder and Wheler, {Jennifer J.} and Filip Janku and Gonzalez-Angulo, {Ana M.} and Mariana Chavez-MacGregor and Vicente Valero and Ueno, {Naoto T.} and Gordon Mills and John Mendelsohn and Hui Yao and Kenneth Aldape and Rajyalakshmi Luthra and Funda Meric-Bernstam",
year = "2015",
month = "1",
day = "1",
doi = "10.1309/AJCPWDEQYCYC92JQ",
language = "English (US)",
volume = "144",
pages = "713--721",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "5",

}

TY - JOUR

T1 - Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing

AU - Roy-Chowdhuri, Sinchita

AU - De Melo Gagliato, Debora

AU - Routbort, Mark J.

AU - Patel, Keyur P.

AU - Singh, Rajesh R.

AU - Broaddus, Russell

AU - Lazar, Alexander J.

AU - Sahin, Aysegul

AU - Alvarez, Ricardo H.

AU - Moulder, Stacy

AU - Wheler, Jennifer J.

AU - Janku, Filip

AU - Gonzalez-Angulo, Ana M.

AU - Chavez-MacGregor, Mariana

AU - Valero, Vicente

AU - Ueno, Naoto T.

AU - Mills, Gordon

AU - Mendelsohn, John

AU - Yao, Hui

AU - Aldape, Kenneth

AU - Luthra, Rajyalakshmi

AU - Meric-Bernstam, Funda

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: The advent of next-generation sequencing (NGS) platforms in the realm of clinical molecular diagnostics provides multigene mutational profiling through massively parallel sequencing. Methods: We analyzed 415 breast carcinoma samples from 354 patients using NGS in known hotspots of 46 commonly known cancer-causing genes. Results: A total of 281 somatic nonsynonymous mutations were detected in 62.1% of patients. TP53 was most frequently mutated (38.8%), followed by PIK3CA (31.7%), AKT1 (6%), and ATM (3.9%), with other mutations detected at a lower frequency. When stratified into clinically relevant therapeutic groups (estrogen receptor [ER]/progesterone receptor [PR]+ human epidermal growth factor receptor 2 [HER2]-, ER/PR+HER2+, ER/PR-HER2+, ER/PR/HER2-), each group showed distinct mutational profiles. The ER/PR+HER2- tumors (n = 132) showed the highest frequency of PIK3CA mutations (38%), while the triple-negative tumors (n = 64) had a significantly higher number of TP53 mutations (62%). Of the 61 patients tested for both primary and metastatic tumors, concordant results were seen in 47 (77%) patients, while 13 patients showed additional mutations in the metastasis. Conclusions: Our results indicate that breast cancers may harbor potentially actionable mutations for targeted therapeutics. Therefore, NGS-based mutational profiling can provide useful information that can guide targeted cancer therapy.

AB - Objectives: The advent of next-generation sequencing (NGS) platforms in the realm of clinical molecular diagnostics provides multigene mutational profiling through massively parallel sequencing. Methods: We analyzed 415 breast carcinoma samples from 354 patients using NGS in known hotspots of 46 commonly known cancer-causing genes. Results: A total of 281 somatic nonsynonymous mutations were detected in 62.1% of patients. TP53 was most frequently mutated (38.8%), followed by PIK3CA (31.7%), AKT1 (6%), and ATM (3.9%), with other mutations detected at a lower frequency. When stratified into clinically relevant therapeutic groups (estrogen receptor [ER]/progesterone receptor [PR]+ human epidermal growth factor receptor 2 [HER2]-, ER/PR+HER2+, ER/PR-HER2+, ER/PR/HER2-), each group showed distinct mutational profiles. The ER/PR+HER2- tumors (n = 132) showed the highest frequency of PIK3CA mutations (38%), while the triple-negative tumors (n = 64) had a significantly higher number of TP53 mutations (62%). Of the 61 patients tested for both primary and metastatic tumors, concordant results were seen in 47 (77%) patients, while 13 patients showed additional mutations in the metastasis. Conclusions: Our results indicate that breast cancers may harbor potentially actionable mutations for targeted therapeutics. Therefore, NGS-based mutational profiling can provide useful information that can guide targeted cancer therapy.

KW - Breast carcinoma

KW - ER positive

KW - Mutational profiling

KW - Next-generation sequencing

KW - Triple negative

UR - http://www.scopus.com/inward/record.url?scp=84947969268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947969268&partnerID=8YFLogxK

U2 - 10.1309/AJCPWDEQYCYC92JQ

DO - 10.1309/AJCPWDEQYCYC92JQ

M3 - Article

C2 - 26486734

AN - SCOPUS:84947969268

VL - 144

SP - 713

EP - 721

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 5

ER -